About Anchiano Therapeutics Ltd. (adapted from Anchiano Therapeutics Ltd. prospectus):
They are a clinical-stage biotechnology company committed to engineering a targeted gene therapy to improve the standard treatment for early-stage bladder cancer, which is one of the most prevalent forms of cancer. Their ordinary shares are listed on the Tel Aviv Stock Exchange Ltd., or the TASE, under the symbol "ANCN".

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.